Existing data suggested that dopamine levels were higher in the hippocampus and cortex of the AD patients (Pan et al., 2019), so inhibition of CCKA receptor-mediated activity might provide insights for treating symptoms of AD. Here, CCKAR is linked to Alzheimer disease.